Agonistic CD40 antibodies and cancer therapy.

PubWeight™: 1.95‹?› | Rank: Top 2%

🔗 View Article (PMC 3590838)

Published in Clin Cancer Res on March 01, 2013

Authors

Robert H Vonderheide1, Martin J Glennie

Author Affiliations

1: Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. rhv@exchange.upenn.edu

Articles citing this

Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48

Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell (2014) 1.55

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell (2016) 1.47

Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol (2013) 1.19

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10

Dendritic cell-targeted vaccines. Front Immunol (2014) 1.08

CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother (2013) 1.08

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity. Nat Cell Biol (2016) 1.02

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res (2014) 0.97

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology (2014) 0.95

Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res (2014) 0.91

Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther (2015) 0.91

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells. Cancer Immunol Res (2016) 0.90

Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89

Immunotherapy and tumor microenvironment. Cancer Lett (2015) 0.88

B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One (2014) 0.88

Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res (2015) 0.85

Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology (2016) 0.84

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget (2016) 0.84

CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep (2016) 0.83

Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer (2013) 0.83

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol (2014) 0.82

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunol Res (2015) 0.82

Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. J Immunother Cancer (2015) 0.80

Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study. Phys Med Biol (2016) 0.79

Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma. J Exp Clin Cancer Res (2015) 0.79

Tumour progression and metastasis. Ecancermedicalscience (2016) 0.79

Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat Commun (2016) 0.79

CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. J Immunol (2016) 0.78

Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78

Kick-starting the cancer-immunity cycle by targeting CD40. Oncoimmunology (2015) 0.78

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78

Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression. Oncoimmunology (2014) 0.78

Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models. PLoS One (2014) 0.78

CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells. Cell Death Dis (2013) 0.78

Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. Mol Ther Nucleic Acids (2016) 0.78

Macrophages and pancreatic ductal adenocarcinoma. Cancer Lett (2015) 0.77

Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev (2015) 0.77

Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy (2015) 0.77

Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Onco Targets Ther (2016) 0.77

Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates. J Immunol (2015) 0.77

Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics. Immunol Res (2013) 0.76

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget (2016) 0.76

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. Oncoimmunology (2014) 0.75

Deploying myeloid cells against myeloma. Oncoimmunology (2015) 0.75

Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins. MAbs (2017) 0.75

Neoadjuvant therapy for pancreatic cancer: an ongoing debate. Therap Adv Gastroenterol (2016) 0.75

CD40 therapy and surgery: a potential immunologic partnership. J Immunother (2013) 0.75

A current perspective on applications of macrocyclic-peptide-based high-affinity ligands. Biopolymers (2016) 0.75

Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol (2013) 0.75

Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. Neuro Oncol (2016) 0.75

Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol (2017) 0.75

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother (2016) 0.75

Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-Ras(G12V)-Induced Squamous Tumors. Cancer Immunol Res (2017) 0.75

Are macrophages in tumors good targets for novel therapeutic approaches? Mol Cells (2014) 0.75

Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents. Oncoimmunology (2014) 0.75

AFM study shows prominent physical changes in elasticity and pericellular layer in human acute leukemic cells due to inadequate cell-cell communication. Nanotechnology (2016) 0.75

CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. J Immunol (2017) 0.75

Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40(+) monocyte differentiation. J Hematol Oncol (2017) 0.75

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95

CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol (1998) 6.83

CD40-CD40 ligand. J Leukoc Biol (2000) 6.28

Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65

FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10

Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med (1999) 2.61

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39

IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23

Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther (2010) 1.94

Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res (2007) 1.75

Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A (2012) 1.62

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2009) 1.52

Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol (2006) 1.52

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res (2013) 1.51

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44

Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood (1994) 1.43

Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia Pac J Clin Oncol (2010) 1.40

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res (2011) 1.39

CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol (2000) 1.35

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34

Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med (2005) 1.31

Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther (2003) 1.22

CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A (2001) 1.22

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology (2013) 1.16

Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med (2006) 1.15

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother (2011) 1.14

Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci U S A (2002) 1.13

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response. Clin Cancer Res (2013) 1.11

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica (2010) 1.10

Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res (1999) 1.10

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med (2011) 1.06

Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res (2001) 1.05

RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther (2008) 1.05

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma (2010) 1.02

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol (2012) 1.02

The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol (2004) 1.01

In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol (2006) 1.00

Giving blood: a new role for CD40 in tumorigenesis. J Exp Med (2006) 0.99

Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin Cancer Res (2013) 0.96

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 0.95

CD40 ligation for immunotherapy of solid tumours. J Immunol Methods (2001) 0.90

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol (2002) 0.88

Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs (2009) 0.88

Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res (2011) 0.88

CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother (2010) 0.80

The application of monoclonal antibodies in the treatment of lymphoma. Methods Mol Med (2000) 0.78

Articles by these authors

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol (2006) 3.59

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 3.38

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood (2010) 2.31

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood (2008) 2.22

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood (2003) 2.04

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood (2011) 1.91

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2002) 1.87

CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol (2008) 1.84

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest (2009) 1.76

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood (2013) 1.58

The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun (2005) 1.52

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol (2002) 1.50

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res (2003) 1.40

Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol (2007) 1.38

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood (2011) 1.34

Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol (2011) 1.16

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood (2007) 1.15

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem (2008) 1.15

Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol (2008) 1.12

CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol (2010) 1.12

Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother (2010) 1.06

Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol (2008) 1.03

Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol (2013) 0.98

Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood (2008) 0.98

CD27 stimulation promotes the frequency of IL-7 receptor-expressing memory precursors and prevents IL-12-mediated loss of CD8(+) T cell memory in the absence of CD4(+) T cell help. J Immunol (2012) 0.94

Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol (2009) 0.94

Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res (2012) 0.93

The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis. Blood (2002) 0.93

Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica (2004) 0.92

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood (2002) 0.92

Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood (2003) 0.92

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother (2013) 0.90

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol (2002) 0.88

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood (2004) 0.87

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res (2013) 0.85

Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol (2011) 0.84

Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction. Acta Neuropathol (2012) 0.83

Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res (2005) 0.83

Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant. Immunology (2010) 0.83

Therapeutic potential of immunostimulatory monoclonal antibodies. Clin Sci (Lond) (2006) 0.82

Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype. Br J Haematol (2009) 0.80

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol (2013) 0.80

Apparent modulation of CD20 by rituximab: an alternative explanation. Blood (2004) 0.80

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B). Eur J Immunol (2012) 0.80

Complement: help or hindrance? Blood (2009) 0.79

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. Eur J Immunol (2012) 0.78

Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination. Tumour Biol (2007) 0.76

Neutrophils: "neu players" in antibody therapy? Blood (2013) 0.76

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood (2003) 0.76

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunol Immunother (2013) 0.76

Multivalent conjugates of poly-gamma-D-glutamic acid from Bacillus licheniformis with antibody F(ab') and glycopeptide ligands. Bioconjug Chem (2003) 0.76

Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. PLoS One (2016) 0.75

Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood. Cancer Immunol Immunother (2014) 0.75